newsfilter
← Latest News
GlobeNewswire·

BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update

Delivered the first global data for any PD-(L)1xVEGF bispecific immunomodulator candidate in combination with an investigational antibody-drug conjugate in lung cancer, with pumitamig plus elfetabart drozuntecanAdvanced